WO2015083179A1 - Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate - Google Patents

Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate Download PDF

Info

Publication number
WO2015083179A1
WO2015083179A1 PCT/IN2014/000109 IN2014000109W WO2015083179A1 WO 2015083179 A1 WO2015083179 A1 WO 2015083179A1 IN 2014000109 W IN2014000109 W IN 2014000109W WO 2015083179 A1 WO2015083179 A1 WO 2015083179A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
methoxy
piperazinyl
hours
formula
Prior art date
Application number
PCT/IN2014/000109
Other languages
French (fr)
Inventor
Ramakrishna Nirogi
Rama Sastri Kambhampati
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201691161A priority Critical patent/EA028038B1/en
Priority to NZ719671A priority patent/NZ719671A/en
Priority to KR1020167013965A priority patent/KR101808792B1/en
Priority to LTEP14725245.6T priority patent/LT3077375T/en
Priority to AP2016009224A priority patent/AP2016009224A0/en
Priority to ES14725245.6T priority patent/ES2638856T3/en
Priority to CA2929309A priority patent/CA2929309C/en
Priority to EP14725245.6A priority patent/EP3077375B1/en
Priority to CN201480065601.9A priority patent/CN105814020B/en
Priority to SI201430348T priority patent/SI3077375T1/en
Priority to MEP-2017-193A priority patent/ME02843B/en
Priority to MX2016006629A priority patent/MX364930B/en
Priority to US15/100,489 priority patent/US9540321B2/en
Priority to DK14725245.6T priority patent/DK3077375T3/en
Application filed by Suven Life Sciences Limited filed Critical Suven Life Sciences Limited
Priority to JP2016535680A priority patent/JP6151453B2/en
Priority to BR112016010788-8A priority patent/BR112016010788B1/en
Priority to AU2014358682A priority patent/AU2014358682B2/en
Priority to RS20170853A priority patent/RS56323B1/en
Publication of WO2015083179A1 publication Critical patent/WO2015083179A1/en
Priority to ZA2016/02954A priority patent/ZA201602954B/en
Priority to IL245619A priority patent/IL245619B/en
Priority to HRP20171245TT priority patent/HRP20171245T1/en
Priority to CY20171100904T priority patent/CY1119298T1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention comprises of process for the synthesis of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate, which is suitable for adaption to large scale manufacturing.
  • 5-HT 6 receptor is one of the potential therapeutic target for the development of cognitive enhancers. 5-HT 6 receptor is localized exclusively in central nervous system, in areas important for learning and memory. In recent years several studies have shown that 5-HT 6 receptor antagonists show beneficial effect on cognition in several animal models. Several 5-HT 6 antagonists advanced into clinic.
  • dimesylate monohydrate is a promising pharmaceutical agent, which is a selective 5-HT 6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
  • the main object of the present invention is to provide a large scale, well optimized manufacturing process for ⁇ l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate monohydrate.
  • Another object of the invention is to provide a process to obtain substantially pure 1 -[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1 -piperazinyl)methy 1]- 1 H-indole dimesylate mono hydrate.
  • Another object of this invention is to show the compatibility of the process to produce l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH- indole dimesylate mono hydrate on a large scale using standard larger scale chemical process equipment.
  • Yet another object of this invention is to provide a commercial process for the production of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate monohydrate on a larger scale.
  • the reaction temperature may range from 15 °C to 35 °C and preferably at a temperature in the range from 20 °C to 30 °C.
  • the duration of the reaction may range from 1.5 hours to 2.5 hours, preferably for a - period of 2 hours.
  • the reaction temperature may range from 15 °C to 40 °C and preferably at a temperature in the range from 20 °C to 35 °C.
  • the duration of the reaction may range from 2.5 hours to 3.5 hours, preferably for a period of 3 hours.
  • the reaction temperature may range from 20 °C to 40 °C and preferably at a temperature ranging from 25 °C to 35 °C.
  • the duration of the reaction may range from 3.5 hours to 4.5 hours, preferably for a period of 4 hours.
  • the reaction temperature may range from 15 °C to 35 °C and preferably at a temperature ranging from 25 °C to 30 °C.
  • the duration of the reaction may range from 18 hours to 22 hours, preferably for a period of 24 hours.
  • the reaction temperature may range from 75 °C to 85 °C and preferably at a temperature in the range from 75 °C to 80 °C.
  • the duration of the reaction may range from 0.5 hour to 1.5 hours, preferably for a period of 45 minutes.
  • Example 1 Preparation of l-[(2-bromophenyI)suIfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyI)methyl]-lH-indole dimesylate monohydrate
  • 1-Methylpiperazine (15 Kg, 0.15 Kg Mole) was charged into a reactor. The mass was cooled to 5 °C - 10 °C. Demineralised water (12 Kg) was added to the above mass slowly, maintaining the mass temperature 10 °C - 20 °C, over a period of 30 minutes. Then added acetic acid (6.16 Kg, 0.103 Kg Mole) to the above mass in 30 minutes, maintaining the mass temperature at 10 °C - 20 °C.
  • the mass was further stirred for another 15 - 20 minutes at 10 °C - 20 °C and aqueous formaldehyde solution (15.67 Kg, 30 % w/v, 0.1567 Kg Mole) was added in 60 minutes maintaining the mass temperature at 15 °C - 20 °C.
  • aqueous formaldehyde solution (15.67 Kg, 30 % w/v, 0.1567 Kg Mole) was added in 60 minutes maintaining the mass temperature at 15 °C - 20 °C.
  • the resultant thick, red colored reaction mass was stirred for another 2 hours at 20 °C - 30 °C to obtain the mannich adduct.
  • Another reactor was charged with 400 L of demineralised water followed by the addition of 20 Kg of lye solution at 20 °C - 35 °C. The content was cooled to 10 °C - 15 °C under stirring. The above reaction mass in the containers was added to the reactor, maintaining the mass temperature at 10 °C - 15 °C in 30 - 40 minutes. The final pH of the solution was adjusted to 9 - 12, if necessary by adding some more lye solution. Then the product was extracted with ethyl acetate (1 x 260 L & 4 x 160 L) maintaining the mass temperature at 10 °C - 15 °C during the entire operations. The pH of aqueous layer was adjusted to 9 - 12 before each extraction.
  • the combined organic layer was washed with (2 x 170 Kg) of brine solution (the brine solution was prepared by adding 95 Kg of vacuum salt to 245 Kg of demineralised water) at 20 °C - 35 °C.
  • the total organic extracts, obtained after the brine washing, were dried over 35 Kg of anhydrous sodium sulfate under stirring for 30 minutes at 20 °C - 35 °C.
  • the organic layer was filtered and charged into another clean reactor.
  • the solvent was removed totally under 500 - 600 mm of Hg vacuum, at 20 °C - 45 °C.
  • the crystalline solid mass was filtered through nutsche and the solid on the nutsche was washed with 18 L of chilled (10 °C - 15 °C) toluene and sucked well. The material was further washed with 20 L of n-hexane and sucked dry to obtain 22.7 Kg of crystalline material.
  • Tetrahydrofuran (85.78 Kg) was charged into a reactor at 20 °C - 35 °C. Then charged the crystallized 5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole (21.5 Kg, 0.0829 Kg Mole) into the reactor at 20 - 35 °C and stirred the mass well. The mass was cooled to 10 °C - 20 °C with chilled water in the jacket. Charged powdered potassium hydroxide (16.1 1 Kg) to the above suspension at 10 °C - 20 °C in 10 minutes under stirring. Slight exotherm was observed. Mass temperature rose from 15.1 °C to 16.3 °C.
  • Acetic acid (8.69 Kg, 0.1448 Kg mole) was dissolved in 137 L of demineralised water and cooled the mass to 10 °C - 15 °C. Charged the above organic extracts into it and stirred for 30 minutes at 10 °C - 15 °C. The mass was allowed to settle for 20 minutes and separated the bottom aqueous acetic acid extract containing the product into a fresh clean reactor.
  • the mass was cooled to 10 °C - 15 °C and the pH of the solution was adjusted to ⁇ 9.5 with chilled caustic lye solution (31 Kg).
  • the product was extracted with (4 x 155 L) of ethyl acetate, maintaining the mass temperature at 10 °C - 15 °C.
  • the pH of aqueous layer was adjusted to ⁇ 9.5 before each extraction.
  • the organic layer was washed with (2 x 1 12 Kg) brine solution (prepared from 51.6 Kg vacuum salt and 175 L water) at 10 °C - 15 °C.
  • the organic layer was dried over 32 Kg of anhydrous sodium sulfate at 20 °C - 35 °C and filtered into another clean reactor. Solvent was removed under 500 - 600 mm Hg by circulating 50 °C - 55 °C water in the jacket of the reactor.
  • the wet solid material (37.76 Kg) was taken in tray drier and air dried at 25 °C - 35 °C for 60 minutes. Further, it was dried at 40 °C - 45 °C for 6 hours to obtain 32.64 Kg of the title product.
  • IR spectra (cm '1 ): 2931, 2786, 1607, 1474, 1369, 1222, 1 178, 1032, 737, 597;
  • the reaction mass was stirred for 24 hours maintaining mass temperature between 25 °C - 30 °C.
  • the mass was filtered through nutsche under nitrogen atmosphere and it was sucked well.
  • the cake, thus obtained, was washed thoroughly with 48 L of ethyl alcohol (slurry wash), sucked well and the cake was again washed with 18 L of ethyl alcohol (spray wash) followed by washing with n-hexane (27 L). It was sucked dry to obtain 70.23 Kg wet cake.
  • the wet cake was taken in a tray drier and dried at 20 °C - 35 °C for 10 hours to obtain 49.43 Kg product (LOD: ⁇ 9.57 %).
  • the carbon slurry was transferred to the reactor and the reaction mass was heated at 75 °C - 80 °C by circulating 80 °C - 90 °C hot water in the reactor jacket for 45 minutes.
  • the mass was filtered hot into another clean reactor, washed the carbon bed with 54.25 Kg of aqueous ethanol (95% ethanol & 5% water) at 75 °C - 80 °C.
  • the contents of the reactor were heated at reflux temperature (76 P C - 78 °C) for 30 minutes to obtain a clear solution.
  • the mass was allowed to cool on its own to 45 °C in 10 hours by applying compressed air in the reactor jacket.
  • Weight of dry product 37.7 Kg
  • Moisture content 2.61 %
  • IR spectra (cm "1 ): 3148, 3012, 161 1, 1590, 1471, 1446, 1439, 1382, 1220, 1 194, 1 180, 1045, 775, 596;
  • the process offers purification of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole base by aqueous acetic acid treatment followed by recrystaliization from methanol and isopropanol mixture to get rid of closely related undesirable impurities.
  • the process involves crystalline products at all the isolated intermediate stages. Therefore, the disclosed process is suitable for further scaling up to ton's level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

A process suitable for adoption to large scale manufacture of 1-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.

Description

PROCESS FOR LARGE SCALE PRODUCTION OF l-[(2-BROMOPHENYL)SULFONYL]-5- METHOXY-3-[(4-MEl,HYI^l-PlPERAZINYL)METHYL]-lFI-m DIMESYLATE MONOHYDRATE FIELD OF INVENTION
The present invention comprises of process for the synthesis of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate, which is suitable for adaption to large scale manufacturing.
BACKGROUND OF THE INVENTION
5-HT6 receptor is one of the potential therapeutic target for the development of cognitive enhancers. 5-HT6 receptor is localized exclusively in central nervous system, in areas important for learning and memory. In recent years several studies have shown that 5-HT6 receptor antagonists show beneficial effect on cognition in several animal models. Several 5-HT6 antagonists advanced into clinic.
l-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-l H- indole. dimesylate monohydrate is a promising pharmaceutical agent, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
Currently l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazin-l- yl)methyl]^lH-indole dimesylate monohydrate is undergoing clinical trials designed to confirm its efficacy. The demand for l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate as a drug substance has increased substantially with the advent of its clinical testing. The future need for much larger amounts is projected due to the intended commercialization of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyI-l-piperazinyl)methyl]-l H-indole dimesylate mono hydrate. For the person skilled in art, it is a well known fact that various parameters will change during the manufacture of a compound on a large scale when compared to the synthetic procedures followed in laboratory. Therefore, there is need to establish and optimize large scale manufacturing process. l-[(2-bromophenyl)sulfonyl]-5-methoxy-3- [(4-methyl-l-piperazinyl)methyl]-lH-indole and it's pharmaceutically acceptable salts and their syntheses were disclosed by Ramakrishna et al. in WO 2004/048330. The process for the preparation of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate monohydrate disclosed herein was proved to be unsatisfactory for adaptation to the large scale manufacturing. Hence it became highly desirable to establish the manufacturing process of l-[(2-bromophenyl)sulfonyI]-5- methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate. Therefore, we established and optimized the manufacturing process of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate» monohydrate, which is amenable to large scale synthesis of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate.
SUMMARY OF THE INVENTION
The main object of the present invention is to provide a large scale, well optimized manufacturing process for ~ l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate monohydrate.
Another object of the invention is to provide a process to obtain substantially pure 1 -[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- 1 -piperazinyl)methy 1]- 1 H-indole dimesylate mono hydrate.
Another object of this invention is to show the compatibility of the process to produce l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH- indole dimesylate mono hydrate on a large scale using standard larger scale chemical process equipment. Yet another object of this invention is to provide a commercial process for the production of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate monohydrate on a larger scale.
DETAILED DESCRIPTION OF THE INVENTION
The large scale manufacturing process for preparation of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indoIe dimesylate monohydrate of formula (I) of the present invention is illustrated by the Sc eme-1 as given below:
Figure imgf000005_0001
Mannich Adduct
Figure imgf000005_0002
Scheme-1
Step (i): Converting 1-Methylpiperazine of formula 1 in presence of acetic acid and aqueous formaldehyde of formula 2 to obtain Mannich adduct. The reaction temperature may range from 15 °C to 35 °C and preferably at a temperature in the range from 20 °C to 30 °C. The duration of the reaction may range from 1.5 hours to 2.5 hours, preferably for a - period of 2 hours.
Step (ii): Reacting the Mannich adduct, as obtained above, with 5-methoxyihdole of formula 3 in presence of methanol to obtain technical Mannich base, 5-methoxy-3-[(4- methyl- l-piperazinyl)methyl]-lH-indole of formula 4. The reaction temperature may range from 15 °C to 40 °C and preferably at a temperature in the range from 20 °C to 35 °C. The duration of the reaction may range from 2.5 hours to 3.5 hours, preferably for a period of 3 hours.
Step (iii): The above obtained technical Mannich base, 5-methoxy-3-[(4-methyl-l- piperazinyI)methyl]-lH-indole of formula 4 was crystallized in toluene by heating the solution to 85 °C - 95 °C for a period of 1 hour, followed by cooling the solution to 10 °C - 15 °C for a period of 3 hours.
Step (iv): The above obtained crystallized 5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]- lH-indole of formula 4 is recrystallized in toluene by heating the solution to 95 °C - 105 °C for a period of 2 hour, followed by cooling the solution to 10 °C - 15 °C for the period of 3 hours.
Step (v): Reacting the above obtained crystalline 5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole of formula 4 with 2-bromobenzenesulfonyl chloride of formula 5 in tetrahydrofuran in presence of potassium hydroxide to obtain l -[(2- bromophenyl)sulfonyl]-5-metTioxy-3-[(4-methyl-l-piperazinyl)methyl]-IH-indole of formula 6. The reaction temperature may range from 20 °C to 40 °C and preferably at a temperature ranging from 25 °C to 35 °C. The duration of the reaction may range from 3.5 hours to 4.5 hours, preferably for a period of 4 hours.
Step (vi): Converting the above obtained l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole of formula 6 in presence of ethanol and methanesulfonic acid to l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate of formula 7. The reaction temperature may range from 15 °C to 35 °C and preferably at a temperature ranging from 25 °C to 30 °C. The duration of the reaction may range from 18 hours to 22 hours, preferably for a period of 24 hours.
Step (vii): Converting the above obtained l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole dimesylate of formula 7 in presence of aqueous ethanol and carbon slurry to obtain l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl- l-piperazinyl)methyl]-lH-indole dimesylate monohydrate of formula (I). The reaction temperature may range from 75 °C to 85 °C and preferably at a temperature in the range from 75 °C to 80 °C. The duration of the reaction may range from 0.5 hour to 1.5 hours, preferably for a period of 45 minutes.
The details of the invention are given in example provided below. The entire process operations were carried out under nitrogen blanket:
Example 1: Preparation of l-[(2-bromophenyI)suIfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyI)methyl]-lH-indole dimesylate monohydrate
Step (i) & (u): Preparation of 5-methoxy-3-[(4-methyl-l-piperazinyI)methyl]-lH- indole
Step (i):
1-Methylpiperazine (15 Kg, 0.15 Kg Mole) was charged into a reactor. The mass was cooled to 5 °C - 10 °C. Demineralised water (12 Kg) was added to the above mass slowly, maintaining the mass temperature 10 °C - 20 °C, over a period of 30 minutes. Then added acetic acid (6.16 Kg, 0.103 Kg Mole) to the above mass in 30 minutes, maintaining the mass temperature at 10 °C - 20 °C. The mass was further stirred for another 15 - 20 minutes at 10 °C - 20 °C and aqueous formaldehyde solution (15.67 Kg, 30 % w/v, 0.1567 Kg Mole) was added in 60 minutes maintaining the mass temperature at 15 °C - 20 °C. The resultant thick, red colored reaction mass was stirred for another 2 hours at 20 °C - 30 °C to obtain the mannich adduct.
Step (ii):
Simultaneously in a separate reactor 125 Kg of methanol was charged at 25 °C - 35 °C. 5-methoxyindole (20 Kg, 0.1359 Kg Mole) was added and the mass was stirred to obtain a clear solution. The mass was cooled to 8 °C - 10 °C in 1.5 hours by circulating brine in the reactor jacket. The Mannich adduct, prepared as above, was charged into the reactor containing cooled methanolic solution of 5-methoxyindole from an addition tank over a period of 50 - 60 minutes, while maintaining the temperature of the reaction mass at 8 °C - 16 °C. After completion of addition, the mass temperature was allowed to rise to 20 °C - 35 °C. Then the reaction mass was further stirred for 3 hours at 20 °C - 35 °C. After completion of the reaction (thin layer chromtography), the reaction mass was discharged into clean and dry containers.
Another reactor was charged with 400 L of demineralised water followed by the addition of 20 Kg of lye solution at 20 °C - 35 °C. The content was cooled to 10 °C - 15 °C under stirring. The above reaction mass in the containers was added to the reactor, maintaining the mass temperature at 10 °C - 15 °C in 30 - 40 minutes. The final pH of the solution was adjusted to 9 - 12, if necessary by adding some more lye solution. Then the product was extracted with ethyl acetate (1 x 260 L & 4 x 160 L) maintaining the mass temperature at 10 °C - 15 °C during the entire operations. The pH of aqueous layer was adjusted to 9 - 12 before each extraction.
The combined organic layer was washed with (2 x 170 Kg) of brine solution (the brine solution was prepared by adding 95 Kg of vacuum salt to 245 Kg of demineralised water) at 20 °C - 35 °C. The total organic extracts, obtained after the brine washing, were dried over 35 Kg of anhydrous sodium sulfate under stirring for 30 minutes at 20 °C - 35 °C.
The organic layer was filtered and charged into another clean reactor. The solvent was removed totally under 500 - 600 mm of Hg vacuum, at 20 °C - 45 °C.
The residual mass, thus obtained, was cooled to room temperature and charged 60 L toluene and stirred the contents at 20 °C - 45 °C for 15 minutes. The solvent was distilled off under reduced pressure (500 - 700 mm of Hg vacuum) at 45 °C - 65 °C. The operation was repeated again by the addition of 60 L toluene and stirring the contents at 20 °C - 45 °C for 15 min. The solvent was distilled off under reduced pressure (500 - 700 mm of Hg vacuum) at 45 °C - 65 °C again to ensure total removal of ethylacetate to avoid losses during recrystallization step. The residual technical product, 5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole, thus obtained, was recrystallized twice, as per the details given below, to obtain the product of desired purity.
Step (Hi): Crystallization of 5-methoxy-3-[(4-methyI-l-piperazinyl)methyl]-lH-indoIe
Charged 61 Kg of toluene into the above reactor which contains the technical product, 5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole. The contents were heated to 85 °C - 95 °C and maintained for an hour at 85 °C - 95 °C. The clear solution, thus obtained, was allowed to cool to 30 °C - 40 °C by circulating room temperature water in the reactor jacket. The mass was further cooled to 10 °C - 15 °C and maintained for 3 hours at the same temperature. The crystalline solid mass was filtered through nutsche and the solid on the nutsche was washed with 18 L of chilled (10 °C - 15 °C) toluene and sucked well. The material was further washed with 20 L of n-hexane and sucked dry to obtain 22.7 Kg of crystalline material.
Step (iv): Recrystallization of 5-methoxy-3-[(4-methyI-l-piperazinyI)methyl]-lH- indole
Charged 40 Kg of toluene into a reactor followed by the addition of the 5-methoxy-
3-[(4-methyl-l-piperazinyl)methyl]-l H-indole (22.7 Kg) obtained in the first crystallization step under stirring. The contents were heated to 95 °C - 105 °C and maintained for 2 hours to obtain a clear solution. The mass was allowed to cool to 35 °C - 40 °C by circulating room temperature water in the jacket. It was further cooled to 10 °C - 15 °C and maintained for 3 hours at 10 °C - 15 °C. The crystalline solid mass was filtered through nutsche and the solid on the nutsche was washed with 8 L of chilled (10 °C - 15 °C) toluene and sucked well. The material was further washed with 15 L of n-hexane and sucked dry. The material was further dried in tray driers at 20 °C - 25 °C to obtain the title product, as off white crystalline powder.
Weight of the crystallized material: 19.95 Kg;
Yield (based on 5-methoxyindole charged): 56.6 %;
HPLC purity: 99.74 %;
Total impurities: 0.26 %;
Assay: 100.6 %; Moisture content: 0.24 %;
Melting range (°C): 139 - 140.6;
IR spectra (cm"1): 3125, 2951, 1875, 1622, 1585, 1492, 1351, 1288, 1215, 1059, 930, 654; Ή - NMR (CDCI3, δ ppm): 2.30 (3H, s), 2.5 (8H, bs), 3.71 (2H, s), 3.86 (3H, s), 6.83 - 6.86 (1H, dd, J = 8.81, 2.7 Hz), 7.01 (1H, d, J = 2.06 Hz), 7.18 - 7.20 (2H, m), 8.91 (1H, s); 13C - NMR (CDCI3, δ ppm): 45.89, 52.79, 53.39, 55.1 1, 55.83, 101.3, 1 1 1.39, 11 1.75, 1 11.81, 124.88, 128.45, 131.48, 153.77;
Mass [M+H]+: 260.3.
Step (v): Preparation of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyI]-lH-indoIe
Tetrahydrofuran (85.78 Kg) was charged into a reactor at 20 °C - 35 °C. Then charged the crystallized 5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole (21.5 Kg, 0.0829 Kg Mole) into the reactor at 20 - 35 °C and stirred the mass well. The mass was cooled to 10 °C - 20 °C with chilled water in the jacket. Charged powdered potassium hydroxide (16.1 1 Kg) to the above suspension at 10 °C - 20 °C in 10 minutes under stirring. Slight exotherm was observed. Mass temperature rose from 15.1 °C to 16.3 °C. The mass was further stirred for 60 minutes at 10 °C - 20 °C. A solution of 2- bromobenzenesulfonyl chloride (27.71 Kg, 0.1084 Kg Mole) in 41.72 Kg tetrahydrofuran was added through addition tank at a constant rate in 60 minutes at 10 °C - 30 °C. The reaction was exothermic and the mass temperature went up from 16 °C to 30 °C. Then removed the chilled water from the jacket and stirred the mass for 3 hours at 25 °C - 35 °C. As the reaction was progressing the mass thickened due to formation of potassium chloride. The progress of the reaction was monitored by thin layer chromatography (Eiuent system: Chloroform and Methanol in 8:2 ratio and the product is relatively non-polar). Since thin layer chromatography shows the presence of starting material (5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole), another lot of 2-bromo benzenesulfonyl chloride (4.5 Kg, 0.0176 Kg Mole) dissolved in 13.71 Kg tetrahydrofuran was added to the reaction mass at 30 °C in 25 minutes. No exotherm observed. The reaction mass was further stirred for 60 minutes at 30 °C - 35 °C. Since the starting material was absent as per thin layer chromatography, it was taken for further workup.
In the mean while charged 360 L demineralised water into another reactor and cooled the contents to 10 °C - 15 °C. The above reaction mass was quenched into chilled water in 60 minutes (mass temperature was 12.1 °C). The pH of the reaction mass was adjusted to ~ 9.5 with an aqueous solution of potassium hydroxide. The product was extracted with (4 x 155 L) ethyl acetate maintaining the mass temperature at 10 °C - 15 °C. The pH of aqueous layer was adjusted to ~ 9.5 before each extraction. The combined organic layer was taken for extraction of the product into aqueous acetic acid. .... j
Acetic acid (8.69 Kg, 0.1448 Kg mole) was dissolved in 137 L of demineralised water and cooled the mass to 10 °C - 15 °C. Charged the above organic extracts into it and stirred for 30 minutes at 10 °C - 15 °C. The mass was allowed to settle for 20 minutes and separated the bottom aqueous acetic acid extract containing the product into a fresh clean reactor.
Further, the extraction and separation process with fresh aqueous acetic acid solution was repeated thrice using 3 x 145 Kg of aqueous acetic acid solution (prepared by dissolving 25.74 Kg, 0.429 Kg Mole of acetic acid in 412 L of demineralised water) following the similar procedure mentioned above, maintaining mass temperature at 10 °C - 15 °C. The combined aqueous acetic acid extracts (containing the product) were taken into the reactor. It was washed with 44 L of ethyl acetate by stirring the mass at 10 °C - 15 °C for 15 minutes, followed by 15 minutes settling. The aqueous product layer was separated. The pH of the aqueous solution was found to be 4.5. The mass was cooled to 10 °C - 15 °C and the pH of the solution was adjusted to ~ 9.5 with chilled caustic lye solution (31 Kg). The product was extracted with (4 x 155 L) of ethyl acetate, maintaining the mass temperature at 10 °C - 15 °C. The pH of aqueous layer was adjusted to ~ 9.5 before each extraction.
The organic layer was washed with (2 x 1 12 Kg) brine solution (prepared from 51.6 Kg vacuum salt and 175 L water) at 10 °C - 15 °C. The organic layer was dried over 32 Kg of anhydrous sodium sulfate at 20 °C - 35 °C and filtered into another clean reactor. Solvent was removed under 500 - 600 mm Hg by circulating 50 °C - 55 °C water in the jacket of the reactor.
To the residual mass in the reactor after solvent removal, charged 36 L of methanol followed by 72 L of isopropanol. The reaction mass was heated to reflux temperature (65 °C - 75 °C). At mass temperature ~ 70 °C a clear solution was obtained. The mass was allowed to cool to 35 - 45 °C with room temperature water circulation in the reactor jacket. Further, it was cooled to 15 °C - 20 °C by circulating brine in the jacket and maintained under stirring for 2 hours at 15 °C - 20 °C. The solids were filtered through nutsche and sucked well under vacuum. The cake was washed with 36 L of isopropanol (15 °C - 20 °C) and sucked well. The wet solid material (37.76 Kg) was taken in tray drier and air dried at 25 °C - 35 °C for 60 minutes. Further, it was dried at 40 °C - 45 °C for 6 hours to obtain 32.64 Kg of the title product.
Overall Yield: 82.3 % (based on Mannich base charged);
HPLC purity: 99.36 %;
Single major impurity: 0.29 %;
Total impurities: 0.64 %;
Assay: 100.5 %;
Loss on drying at 105 °C: 0.21 %;
Melting range (°C): 128.1 - 129.2;
IR spectra (cm'1): 2931, 2786, 1607, 1474, 1369, 1222, 1 178, 1032, 737, 597;
Ή - NMR (CDC13, δ ppm): 2.29 (3H, s), 2.32 - 2.50 (8H, bs), 3.62 (2H, s), 3.83 (3H, s),
6.83 - 6.86 (1H, dd, J = 8.98, 2.46 Hz), 7.19 - 7.20 (1H, d, J = 2.42 Hz), 7.36 - 7.40 (1 H, dt,
J.= 7.68, 1.56 Hz), 7.45 - 7.47 (1H, t, J = 7.50 Hz), 7.53 - 7.55 (1H, d, J = 9.00, Hz), 7.64 -
7.66 (2H, m), 8.03 - 8.05 (1H, dd, J = 7.89, 1.54 Hz);
13C - NMR (CDCI3, δ ppm): 45.94, 53.07, 53.33, 55.17, 55.60, 103.28, 1 13.20, 1 13.69,
117.83, 120.42, 127.05, 127.69, 129.57, 131.16, 131.57, 134.48, 135.90, 138.09, 156.12;
Mass [M+Hf: 478.1, 480.1.
Step (vi): Preparation of l-[(2-bromophenyl)sulfonyI]-5-methoxy-3-[(4-methyI-l- piperazinyl)methyI]-lH-indoIe dimesylate Charged 182.5 Kg of absolute ethanol into a reactor at 20 °C - 35 °C. Then charged l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole - (obtained in the above step, 32.02 Kg, 0.067 Kg Mole) under stirring in a single lot at 20 °C - 35 °C (mass temperature), added methanesulfonic acid (13.9 Kg, 0.1446 Kg Mole) slowly to the above reaction mass from a holding tank in 60 minutes, maintaining mass temperature at 20 °C - 35 °C. No clear solution was obtained at any stage. The mass became thick, but stirrable. The reaction mass was stirred for 24 hours maintaining mass temperature between 25 °C - 30 °C. The mass was filtered through nutsche under nitrogen atmosphere and it was sucked well. The cake, thus obtained, was washed thoroughly with 48 L of ethyl alcohol (slurry wash), sucked well and the cake was again washed with 18 L of ethyl alcohol (spray wash) followed by washing with n-hexane (27 L). It was sucked dry to obtain 70.23 Kg wet cake. The wet cake was taken in a tray drier and dried at 20 °C - 35 °C for 10 hours to obtain 49.43 Kg product (LOD: ~ 9.57 %).
Weight of product on dry basis: 44.65 Kg
Yield of salt: Quantitative (based on l -[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methy 1- 1 -piperaziny l)methy 1]- 1 H- indo le charged) ;
HPLC purity: 99.69 %;
Total impurities: 0.31 %;
Salt content: 27.39 %.
Step (vii): Preparation of l-[(2-bromop enyl)sulfonyI]-5-methoxyr3-[(4-methyI-l- piperazinyl)methyl]-lH-indole dimesylate monohydrate
Charged 415 Kg of aqueous ethanol (95 % ethanol & 5 % water) into a reactor, followed by the addition of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate (44.65 Kg, 0.0666 Kg Mole, obtained from the above step) at 20 °C - 35 °C. In the meanwhile carbon slurry was prepared separately by adding 6.7 Kg of carbon powder into 18 Kg of aqueous ethanol (95 % ethanol & 5 % water). Then the carbon slurry was transferred to the reactor and the reaction mass was heated at 75 °C - 80 °C by circulating 80 °C - 90 °C hot water in the reactor jacket for 45 minutes. The mass was filtered hot into another clean reactor, washed the carbon bed with 54.25 Kg of aqueous ethanol (95% ethanol & 5% water) at 75 °C - 80 °C. The contents of the reactor were heated at reflux temperature (76 PC - 78 °C) for 30 minutes to obtain a clear solution. The mass was allowed to cool on its own to 45 °C in 10 hours by applying compressed air in the reactor jacket. It was further cooled to 10 °C - 15 °C with chilled water circulated in the jacket and maintained under stirring for 3 hours. Filtered the crystalline material through a centrifuge and the material on the centrifuge was washed with 18.6 Kg of aqueous ethanol (95 % ethanol & 5 % water) (10 °C - 15 °C) and spin dried. The whole material was air dried in a tray drier for 14 hours at 20 °C - 35 °C. The material was milled, sieved and collected in poly bag to obtain 37.7 Kg of the title product. The uniform material was sampled for analysis.
Weight of dry product: 37.7 Kg;
Yield of salt: 82.2 %;
HPLC purity: 99.7 %;
Single impurity: 0.3 %;
Assay: 99.9 %;
Moisture content: 2.61 %;
Salt content (Dimesylate) 27.56 %;
Melting range (°C): 218.0 - 220.0;
IR spectra (cm"1): 3148, 3012, 161 1, 1590, 1471, 1446, 1439, 1382, 1220, 1 194, 1 180, 1045, 775, 596;
Ή - NMR (D20, δ ppm): 2.65 (6H, s), 2.89 (3H, s), 3.52 (8H, bs), 3.70 (3H, s), 4.46 (2H, s), 6.75 - 6.78 (1H, dd, J = 9.07, 2.02 Hz), 7.10 - 7.1 1 (1H, d, J = 1.9 Hz), 7.32 - 7.38 (2H, m), 7.44 - 7.47 (1H, t, J = 7.6 Hz), 7.54 - 7.56 (1H, dd, J = 7.79 Hz), 8.04 (1H, s), 8.14 - 8.16 (lH, d, J = 7.94 Hz);
, C - NMR (δ ppm): 38.42, 42.79, 48.19, 50.35, 55.80, 102.57, 108.20, 113.72, 114.07, 1 19.62, 128.25, 128.56, 130.17, 131.80, 132.15, 135.28, 135.95, 156.21 ;
Mass [M+H]+: 478, 480. Advantages:
1. In this patent application, robust and well optimized -process for the manufacture of 1- [(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate mono hydrate is disclosed. This process is suitable for large scale manufacturing of .. l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate mono hydrate without any trial and error.
2. Pharmaceutically acceptable dimesylate salt of the l-[(2-bromophenyl)sulfonyl]-5- methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole base was manufactured utilizing commercially available and economically viable raw materials.
3. The process offers purification of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole base by aqueous acetic acid treatment followed by recrystaliization from methanol and isopropanol mixture to get rid of closely related undesirable impurities.
4. The process described in this patent application does not involve column purifications at any stage. Crystallization methods were developed at each stage to obtain pure product, thereby eliminating the material handling issues.
5. The process involves crystalline products at all the isolated intermediate stages. Therefore, the disclosed process is suitable for further scaling up to ton's level.

Claims

We claim:
1. A process suitable for large scale production of l-[(2-bromophenyl)sulfonyl]-5- methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesytate monohydrate of formula (I),
Figure imgf000016_0001
which comprises:
Step (i): reacting 1 -Methylpiperazi formula 1
Figure imgf000016_0002
1
in presence of acetic acid and aqueous formaldehyde of formula 2 at a temperature in the range of 15 °C to 35 °C for a period of 1.5 hours to 2.5 hours to obtain annich adduct;
Figure imgf000016_0003
Mannich Adduct
Step (ii): reacting the Mannich adduct with 5-methoxyindole of formula 3
Figure imgf000016_0004
in presence of methanol at a temperature in the range of 15 °C to 40 °C for a period of 2.5 hours to 3.5 hours to obtain 5-methoxy-3-[(4-methyl-l -piperazinyl) methyl]- lH-indole of formula
Figure imgf000017_0001
Step (iii): crystallizing 5-methoxy-3-[(4-methyl-l -piperazinyl) methyl]- IH-indole of formula 4 in toluene by heating the solution to 85 oC - 95 oC for a period of 1 hour, followed by cooling the solution to 10 oC - 15 oC for the period of 3 hours; Step (iv): recrystallizing 5-methoxy-3-[(4-methyl-l -piperazinyl) methyl]-lH- indole of formula 4 in toluene by heating the solution to 95 oC - 105 oC for a period of 2 hour, followed by cooling the solution to 10 oC - 15 oC for a period of 3 hours;
Step (v): reacting the above obtained crystalline 5-methoxy-3-[(4-methyl-l- piperazinyl) methyl]- IH-indole of formula 4 with 2-bromobenzenesulfonyl chloride of formula 5;
Figure imgf000017_0002
in presence of tetrahydrofuran and potassium hydroxide at a temperature in the range of 20 °C to 40 °C for a period of 3.5 hours to 4.5 hours to obtain l-[(2- bromophenyI)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole of formula 6;
Figure imgf000017_0003
6 Step (vi): converting l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole of formula 6 in presence of ethanol and methanesulfonic acid at a temperature in the range of 15 °Gto 35 °C for a period of 18 hours to 22 hours to obtain l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole dimesylate of formula 7;
Figure imgf000018_0001
7
Step (vii): converting l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l- piperazinyl)methyl]-lH-indole dimesylate of formula 7 in presence of aqueous ethanol and carbon slurry at a temperature in the range of 75 °C to 85 °C for a period of 0.5 hours - 1.5 hours to obtain l-[(2-bromophenyl)sulfonyI]-5-methoxy- 3-[(4-methyl-l -piperazinyl)methyl]-lH-indole dimesylate monohydrate of formula (I).
2. The process as claimed in claim 1, wherein the temperature used in Step (i) is 20 °C to 30 °C.
3. The process as claimed in claim 1, wherein the duration of reaction in Step (i) is 2 hours.
4. The process as claimed in claim 1, wherein the temperature used in Step (ii) is 20 °C to 35 °C.
5. The process as claimed in claim 1, wherein the duration of reaction in Step (ii) is 3 hours.
6. The process as claimed in claim 1 , wherein the temperature used in Step (v) is 25 °C to 35 °C.
7. The process as claimed in claim 1, wherein the duration of reaction in Step (v) is 4 hours.
8. The process as claimed in claim 1, wherein the temperature used in Step (vi) is 25 °C to 30 °C.
9. The process as claimed in claim 1, wherein the duration of reaction in Step (vi) is 24 hours.
10. The process as claimed in claim 1, wherein the temperature used in Step (vii) is 75 °C to 80 °C.
1 1. The process as claimed in claim 1, wherein the duration of reaction in Step (vii) is 45 minutes.
12. The process as claimed in claim 1, wherein ; the purity of l-[(2- bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate is > 99 %.
13. The process for preparation of l-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4- methyl-l-piperazinyl)methyl]-lH-indole dimesylate monohydrate of formula (I) is substantially as herein described with reference to the Example 1.
PCT/IN2014/000109 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate WO2015083179A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
BR112016010788-8A BR112016010788B1 (en) 2013-12-02 2014-02-20 PROCESS FOR THE LARGE-SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE
KR1020167013965A KR101808792B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
LTEP14725245.6T LT3077375T (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
AP2016009224A AP2016009224A0 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
ES14725245.6T ES2638856T3 (en) 2013-12-02 2014-02-20 Process for large-scale production of 1 - [(2-bromophenyl) sulfonyl] -5-methoxy-3 - [(4-methyl-1-piperazinyl) methyl] -1H-indole monohydrate dimesylate
CA2929309A CA2929309C (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
EP14725245.6A EP3077375B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
CN201480065601.9A CN105814020B (en) 2013-12-02 2014-02-20 Method for mass producing 1 [(2 bromophenyl) sulfonyl] 5 methoxyl group 3 [(4 methyl, 1 piperazinyl) methyl] 1H indoles dimethanesulfonate monohydrates
SI201430348T SI3077375T1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-((2-bromophenyl)sulfonyl)-5-methoxy-3-((4-methyl-1-piperazinyl)methyl)-1h-indole dimesylate monohydrate
MEP-2017-193A ME02843B (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
MX2016006629A MX364930B (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl] -5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate.
EA201691161A EA028038B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
DK14725245.6T DK3077375T3 (en) 2013-12-02 2014-02-20 PROCEDURE FOR LARGE SCALE PREPARATION OF 1 - [(2-BROMPHENYL) SULPHONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-INDOL-DIMESYLATE-MONOHYDRATE
US15/100,489 US9540321B2 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
JP2016535680A JP6151453B2 (en) 2013-12-02 2014-02-20 Large-scale synthesis of 1-[(2-bromophenyl) sulfonyl] -5-methoxy-3-[(4-methyl-1-piperazinyl) methyl] -1H-indole dimesylate monohydrate
NZ719671A NZ719671A (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
AU2014358682A AU2014358682B2 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
RS20170853A RS56323B1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
ZA2016/02954A ZA201602954B (en) 2013-12-02 2016-05-03 Process for large scale production of 1-{(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
IL245619A IL245619B (en) 2013-12-02 2016-05-11 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
HRP20171245TT HRP20171245T1 (en) 2013-12-02 2017-08-16 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
CY20171100904T CY1119298T1 (en) 2013-12-02 2017-08-28 PROCEDURE FOR PRODUCING LARGE-SCALE OF 1- (2-BROMOPHENYL) SULFONYL] -5-METHOXY-3 - [(4-METHYL-1-PIPERAZINYL) METHYL] -1H-1 NIDOLEYM MON

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN5537/CHE/2013 2013-12-02
IN5537CH2013 IN2013CH05537A (en) 2013-12-02 2014-02-20

Publications (1)

Publication Number Publication Date
WO2015083179A1 true WO2015083179A1 (en) 2015-06-11

Family

ID=54199404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000109 WO2015083179A1 (en) 2013-12-02 2014-02-20 Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate

Country Status (28)

Country Link
US (1) US9540321B2 (en)
EP (1) EP3077375B1 (en)
JP (1) JP6151453B2 (en)
KR (1) KR101808792B1 (en)
CN (1) CN105814020B (en)
AP (1) AP2016009224A0 (en)
AU (1) AU2014358682B2 (en)
BR (1) BR112016010788B1 (en)
CA (1) CA2929309C (en)
CY (1) CY1119298T1 (en)
DK (1) DK3077375T3 (en)
EA (1) EA028038B1 (en)
ES (1) ES2638856T3 (en)
HK (1) HK1226396B (en)
HR (1) HRP20171245T1 (en)
HU (1) HUE036008T2 (en)
IL (1) IL245619B (en)
IN (1) IN2013CH05537A (en)
LT (1) LT3077375T (en)
ME (1) ME02843B (en)
MX (1) MX364930B (en)
NZ (1) NZ719671A (en)
PL (1) PL3077375T3 (en)
PT (1) PT3077375T (en)
RS (1) RS56323B1 (en)
SI (1) SI3077375T1 (en)
WO (1) WO2015083179A1 (en)
ZA (1) ZA201602954B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017199072A1 (en) 2016-05-18 2017-11-23 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
WO2017199070A1 (en) 2016-05-18 2017-11-23 Suven Life Sciences Limited Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
WO2017199071A1 (en) 2016-05-18 2017-11-23 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
WO2018065869A1 (en) 2016-10-03 2018-04-12 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 antagonist
KR20200019747A (en) * 2017-07-03 2020-02-24 수벤 라이프 사이언시스 리미티드 New Uses of Pure 5-HT6 Receptor Antagonists
WO2021111320A1 (en) 2019-12-02 2021-06-10 Suven Life Sciences Limited Methods for treating behavioral and psychological symptoms in patients with dementia
US20210346374A1 (en) * 2016-10-03 2021-11-11 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 receptor antagonist

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020398082A1 (en) 2019-12-02 2022-06-16 Suven Life Sciences Limited Treating behavioral and psychological symptoms in dementia patients
CN111233737B (en) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 Salts of heteroaromatic derivatives and use thereof
CN111362858B (en) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 Salts of heteroaromatic derivatives and use thereof
CN111362859B (en) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 Salts of heteroaromatic derivatives and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048330A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
WO2004055026A1 (en) * 2002-12-18 2004-07-01 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749846B1 (en) * 1996-06-17 1998-09-11 Pf Medicament METHANESULFONATE SALT OF ARYLPIPERAZINE DERIVED FROM TRYPTAMINE AND ITS SOLVATES FOR PHARMACEUTICAL USE
NZ572744A (en) * 2006-06-12 2011-05-27 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048330A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
WO2004055026A1 (en) * 2002-12-18 2004-07-01 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016407428B2 (en) * 2016-05-18 2019-11-21 Suven Life Sciences Limited Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist
WO2017199070A1 (en) 2016-05-18 2017-11-23 Suven Life Sciences Limited Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
WO2017199071A1 (en) 2016-05-18 2017-11-23 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
US11458135B2 (en) 2016-05-18 2022-10-04 Suven Life Sciences Limited Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors
CN109069449A (en) * 2016-05-18 2018-12-21 苏文生命科学有限公司 Pure 5-HT6The combination of receptor antagonist and nmda receptor antagonist
WO2017199072A1 (en) 2016-05-18 2017-11-23 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
EA038087B1 (en) * 2016-05-18 2021-07-05 Сувен Лайф Сайенсиз Лимитед Triple pharmaceutical combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist, use of said combination and a pharmaceutical composition thereof in treating cognitive disorders and method of such treatment
AU2016407427B2 (en) * 2016-05-18 2019-11-21 Suven Life Sciences Limited Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors
AU2016407426B2 (en) * 2016-05-18 2019-11-28 Suven Life Sciences Limited Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist
US11253514B2 (en) 2016-05-18 2022-02-22 Suven Life Sciences Limited Triple combination of pure 5-HT6 receptor antagonists, acetylcholinesterase inhibitors and NMDA receptor antagonist
US11116764B2 (en) 2016-05-18 2021-09-14 Suven Life Sciences Limited Combination of pure 5-HT6 receptor antagonists with NMDA receptor antagonist
EA036301B1 (en) * 2016-05-18 2020-10-23 Сувен Лайф Сайенсиз Лимитед Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
EA036347B1 (en) * 2016-05-18 2020-10-29 Сувен Лайф Сайенсиз Лимитед Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors
AU2017339755B2 (en) * 2016-10-03 2019-11-07 Suven Life Sciences Limited Pharmaceutical compositions of 5-HT6 antagonist
EA036235B1 (en) * 2016-10-03 2020-10-16 Сувен Лайф Сайенсиз Лимитед Pharmaceutical compositions of 5-ht6 antagonist
US20210346374A1 (en) * 2016-10-03 2021-11-11 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 receptor antagonist
WO2018065869A1 (en) 2016-10-03 2018-04-12 Suven Life Sciences Limited Pharmaceutical compositions of 5-ht6 antagonist
US20210338661A1 (en) * 2017-07-03 2021-11-04 Suven Life Sciences Limited New uses of a pure 5-ht 6 receptor antagonist
KR20200019747A (en) * 2017-07-03 2020-02-24 수벤 라이프 사이언시스 리미티드 New Uses of Pure 5-HT6 Receptor Antagonists
KR102508303B1 (en) * 2017-07-03 2023-03-09 수벤 라이프 사이언시스 리미티드 Novel uses of pure 5-HT6 receptor antagonists
WO2021111320A1 (en) 2019-12-02 2021-06-10 Suven Life Sciences Limited Methods for treating behavioral and psychological symptoms in patients with dementia

Also Published As

Publication number Publication date
HUE036008T2 (en) 2018-06-28
PL3077375T3 (en) 2017-11-30
DK3077375T3 (en) 2017-09-11
KR20160094945A (en) 2016-08-10
IL245619B (en) 2018-12-31
EP3077375A1 (en) 2016-10-12
EA028038B1 (en) 2017-09-29
CY1119298T1 (en) 2018-02-14
ME02843B (en) 2018-01-20
LT3077375T (en) 2017-09-11
US9540321B2 (en) 2017-01-10
KR101808792B1 (en) 2017-12-13
ZA201602954B (en) 2017-07-26
CA2929309A1 (en) 2015-06-11
JP6151453B2 (en) 2017-06-21
RS56323B1 (en) 2017-12-29
NZ719671A (en) 2017-03-31
HK1226396B (en) 2017-09-29
AU2014358682B2 (en) 2016-10-20
PT3077375T (en) 2017-09-05
CN105814020B (en) 2018-04-17
AP2016009224A0 (en) 2016-05-31
BR112016010788B1 (en) 2023-03-21
MX364930B (en) 2019-05-14
CN105814020A (en) 2016-07-27
SI3077375T1 (en) 2017-10-30
IL245619A0 (en) 2016-06-30
JP2016539133A (en) 2016-12-15
MX2016006629A (en) 2016-08-08
EP3077375B1 (en) 2017-07-19
ES2638856T3 (en) 2017-10-24
BR112016010788A8 (en) 2018-01-30
IN2013CH05537A (en) 2015-06-12
HRP20171245T1 (en) 2017-10-20
US20160297759A1 (en) 2016-10-13
AU2014358682A1 (en) 2016-06-02
EA201691161A1 (en) 2016-09-30
CA2929309C (en) 2018-07-03

Similar Documents

Publication Publication Date Title
AU2014358682B2 (en) Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
WO2012168364A1 (en) Apixaban preparation process
JP2018513219A (en) Fused ring pyrimidine amino derivatives, process for producing the same, intermediates, pharmaceutical compositions and applications
CN111630049B (en) Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof
CA2908879A1 (en) Crystal of pyrrole derivative and method for producing the same
EP3413891B1 (en) Processes for the preparation of highly pure prucalopride succinate
JP6904519B2 (en) Manufacturing methods and intermediates for synthesizing intermediates for the antitumor drug niraparib
WO2018214676A1 (en) Buagafuran active pharmaceutical ingredient and preparation method and application thereof
US7745429B2 (en) Crystal forms of olanzapine and processes for their preparation
ITMI20090663A1 (en) PROCEDURE FOR THE PURIFICATION OF PALIPERIDONE
CN104557877A (en) Avanafil intermediate as well as preparation method and application thereof
JP2015038053A (en) Method for producing 4-(2-methyl-1-imidazolyl)-2,2-phenylbutane amide
JP6385580B2 (en) Process for large-scale production of N- [4- (1-cyclobutylpiperidin-4-yloxy) phenyl] -2- (morpholin-4-yl) acetamide dihydrochloride
EP1730153B1 (en) Isopropanol water solvate of olanzapine
EP3180333B1 (en) Process for large scale production of 1-isopropyl-3-{5- [1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1h-indazole oxalate
EP3180001B1 (en) Active metabolite of 1-[(2-bromophenyl) sulfonyl]-5-methoxy-3- [(4-methyl-1-piperazinyl) methyl]-1h-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite
WO2012035554A1 (en) An improved process for the preparation of highly pure paliperidone
EA039290B1 (en) Method for isolation and purification of naltrexone
EA042468B1 (en) METHODS FOR PRODUCING INTERMEDIATES FOR THE SYNTHESIS OF THE MDM2 INHIBITOR
NO330342B1 (en) New Process for Preparation of Imidazolyl Compounds
KR20140118154A (en) Process for the preparation of high purity olanzapine and crystalline form II thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14725245

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2929309

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 245619

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/006629

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016010788

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20167013965

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15100489

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016535680

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014358682

Country of ref document: AU

Date of ref document: 20140220

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014725245

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014725245

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201691161

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112016010788

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160512